Skip to main content

Table 1 The comparison of clinical and genetic features between LINC00649-high and LINC00649-low groups. A total of 145 patients from TCGA and 451 patients form BeatAML database were included. The molecular and cytogenetic risk of LINC00649-low group is more adverse than that of LINC00649-high group (p < 0.001)

From: LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia

  TCGA beatAML
LINC00649-low group (n = 72) LINC00649-high group (n = 73) p value LINC00649-low group (n = 225) LINC00649-high group (n = 226) p value
Age (year) 55.21 ± 2.011 54.47 ± 2.137 0.81 59.81 ± 1.055 53.62 ± 1.356 0.049
Gender    0.589    0.775
 Female 27 31   95 98  
 Male 35 31   130 127  
Race    0.838    0.801
 White 47 45   39 37  
 Other races 15 17   186 188  
Mutation count 9.82 ± 0.624 9.77 ± 0.803 0.962 NA NA  
Risk stratification of cytogenetics   0.001    NA
 Good 0 15   NA NA  
 Intermediate 48 28   NA NA  
 Poor 14 19   NA NA  
Risk stratification of molecular mutation   0.001    0.002
 Good 0 15   99 70  
 Intermediate 45 28   44 73  
 Poor 17 19   82 82  
WBC 47.498 ± 5.091 22.705 ± 5.040 0.001 34.807 ± 2.979 27.615 ± 3.465 0.112